Join
Live feed
·
INSIDERFilingvia Quantisnow
Karyopharm Therapeutics Inc. logo

EVP, Chief Development Officer Poulton Stuart sold $835 worth of shares (191 units at $4.37), decreasing direct ownership by 0.70% to 27,223 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KPTI· Karyopharm Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KPTI (Karyopharm Therapeutics Inc.) and more on Quantisnow.